Christopher Deitrick

Also affiliated with UPMC Hillman Cancer Center

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial”.

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial

Cancer Cell(2024)10.1016/j.ccell.2024.10.007

N/A

1.3DataRank · unranked

59 citations

Robert M. Morrison, Amiran Dzutsev, Arivarasan Karunamurthy, Joë-Marc Chauvin, F. Amatore +48 more

605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0605

N/A

0DataRank · unranked

4 citations

Joë-Marc Chauvin, Robert Morrison, Yulong Bai, Jie Sun, Hong Wang +22 more

Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma

Research Square(2022)10.21203/rs.3.rs-2235839/v1

N/A

0DataRank · unranked

1 citations

Arivarasan Karunamurthy, Joë-Marc Chauvin, Robert M. Morrison, Yulong Bai, Jie Sun +40 more

Tumor cell p38 inhibition to overcome immunotherapy resistance

Research Square(2023)10.21203/rs.3.rs-3183496/v1

N/A

0DataRank · unranked

5 citations

Rebekah Dadey, Ryan C. Augustin, Sarah Newman, Krishna B. Singh, Rose Doerfler +26 more

Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma

medRxiv(2025)10.1101/2025.11.04.25339499

N/A

0DataRank · unranked

2 citations

Anthony R. Cillo, Shuaichao Wang, Arivarasan Karunamurthy, Ryan Massa, Anjali Rohatgi +16 more

1340 Lead-in therapy targeting PD1 and/or LAG3 distinguishes differential impacts upon the immune response in first-line treatment of metastatic melanoma

(2025)10.1136/jitc-2025-sitc2025.1340

N/A

0DataRank · unranked

0 citations

Anthony R. Cillo, Shuaichao Wang, Arivarasan Karunamurthy, Ryan Massa, Anjali Rohatgi +15 more